Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads heart rhythms to unmask silent heart disease

NCT ID NCT06511505

Diagnosis Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This trial tests whether an artificial intelligence tool can help doctors detect undiagnosed atrial fibrillation and structural heart disease from routine electrocardiograms (ECGs). About 1,000 healthcare providers are randomly assigned to either receive AI-generated risk alerts for their patients or not, and researchers compare how often new heart conditions are diagnosed. The goal is to see if this AI approach improves detection and guides further testing in everyday clinical practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-enabled ECG screening tool (rECHOmmend and ECG-AF algorithms) that analyzes 12-lead ECG recordings to flag risk of atrial fibrillation and structural heart disease
What this could lead to
If effective, this AI tool could help doctors catch hidden heart conditions earlier, potentially preventing complications like stroke or heart failure.
What could go wrong
The AI may produce false alarms or miss cases, and it's unclear if acting on its alerts will truly improve patient outcomes in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Atrial fibrillation algorithm 1. Age 65 or over 2. ECG obtained as part of routine clinical care 2. Structural heart disease algorithm 1. Age 40 or over 2. ECG obtained as part of routine clinical care Exclusion Criteria: 1. Atrial fibrillation algorithm 1. No history of AF 2. No permanent pacemaker (PPM) or implantable cardioverter defibrillator (ICD) 3. No recent cardiac surgery (within the preceding 30 days) 2. Structural heart disease algorithm 1. No history of SHD 2. No echocardiogram within the past 1 year

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arrhythmia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac atrial fibrillation cardiac rhythm disease cardiovascular disorder heart valve disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arrhythmia Atrial fibrillation Cardiovascular diseases Valvular disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.